From Pulse 2.0 · Amit Chowdhry · · 50s
Seragy Secures €12 Million Financing For Neurodegenerative Biomarkers
Seragy's €12 million funding accelerates biomarker tech for neurodegenerative diseases.
In brief
Seragy's €12 million funding accelerates biomarker tech for neurodegenerative diseases. Seragy Holding secured €12 million to advance its SeRAS platform for measuring protein aggregation in neurodegenerative diseases. Originally reported by Pulse 2.0.
Financing secured
Seragy Holding has secured €12 million in financing to accelerate development of its proprietary SeRAS platform and expand laboratory capabilities for neurodegenerative diseases and other conditions driven by pathological protein aggregation.
Investors include
The financing is backed by Commerzbank, the Mittelständische Beteiligungsgesellschaft, or MBG, and the State of Lower Saxony.
SeRAS platform
Seragy develops quantitative biomarkers for proteopathies including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.
Technology details
SeRAS combines seeding-based biochemistry with high-sensitivity optics, automated data analysis, software algorithms, and micromechanical components.
Applications
Seragy plans to support pharmaceutical and biotechnology companies from early drug discovery through preclinical and clinical development.
The headline
Seragy Holding secured €12 million to advance its SeRAS platform for measuring protein aggregation in neurodegenerative diseases.
